Patent · US Active

IDO inhibitors

US9758492B2 · kind B2 · utility

2Cited by

0References

11Claims

0Family size

Assignees

Bristol-Myers Squibb Company · US
Syngene International Limited · IN

Inventors

Jay A. Markwalder · New London, US
Steven P. Seitz · Swarthmore, US
James Aaron Balog · Lambertville, US
Audris Huang · Princeton, US
Sunil Kumar Mandal · Bengaluru, IN
Shefali Srivastava · Savanuru, IN
David K. Williams · Cinnaminson, US
Libing Chen · Newtown, US

Key dates

Filing date	Aug 26, 2014
Grant date	Sep 12, 2017
Priority date	—
Expiry date	Aug 26, 2034

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or autoimmune diseases utilizing the compounds of the invention.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.